A new FDA approval might carry a hope for those suffering from idiopathic pulmonary fibrosis, a scarring of the lungs. The disease affects approximately 100,000 Americans and kills many of them in three to five years. The two approved drugs are Esbriet (pirfenidone) and Ofev (nintedanib), which have been developed by Roche and Boehringer Ingelheim, respectively. Even though these two medications do not improve the symptoms, they slow the lung function declining rate. However, the exact mechanism of action is still unknown. These are the first two medications that got approved for this disease. How often do you see patients with idiopathic pulmonary fibrosis in your practice?
To read more, please visit The New York Times.
Image courtesy of [dream designs] / FreeDigitalPhotos.net